Home
/
BeOne Medicines Ltd.
/
Financials
/
Quarterly
BeOne Medicines Ltd. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that BeOne Medicines Ltd. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2018
Sep 30, 2018
$54.20M
Nov 8, 2018
Q2
2018
Jun 30, 2018
$52.80M
Aug 9, 2018
Q1
2018
Mar 31, 2018
$32.54M
May 9, 2018
Q3
2018
Sep 30, 2017
$220.21M
Nov 8, 2018
Q2
2018
Jun 30, 2017
$0
Aug 9, 2018
Q3
2017
Sep 30, 2016
$1.07M
Nov 13, 2017
Q2
2017
Jun 30, 2016
$393.0K
Aug 9, 2017
Q1
2017
Mar 31, 2016
$677.0K
May 10, 2017
Q3
2016
Sep 30, 2015
$1.38M
Nov 10, 2016
Q2
2016
Jun 30, 2015
$1.38M
Aug 10, 2016
Q1
2016
Mar 31, 2015
$1.38M
May 12, 2016
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$1.41B
Nov 6, 2025
Q2
2025
Jun 30, 2025
$1.32B
Aug 6, 2025
Q1
2025
Mar 31, 2025
$1.12B
May 7, 2025
Q3
2025
Sep 30, 2024
$1.00B
Nov 6, 2025
Q2
2025
Jun 30, 2024
$929.17M
Aug 6, 2025
Q1
2025
Mar 31, 2024
$751.65M
May 7, 2025
Q3
2024
Sep 30, 2023
$781.31M
Nov 12, 2024
Q2
2024
Jun 30, 2023
$595.26M
Aug 7, 2024
Q1
2024
Mar 31, 2023
$447.80M
May 8, 2024
Q3
2023
Sep 30, 2022
$387.63M
Nov 9, 2023
Q2
2023
Jun 30, 2022
$341.57M
Aug 2, 2023
Q1
2023
Mar 31, 2022
$306.63M
May 4, 2023
Q3
2022
Sep 30, 2021
$206.44M
Nov 9, 2022
Q2
2022
Jun 30, 2021
$149.99M
Aug 8, 2022
Q1
2022
Mar 31, 2021
$605.87M
May 9, 2022
Q3
2021
Sep 30, 2020
$91.08M
Nov 4, 2021
Q2
2021
Jun 30, 2020
$65.64M
Aug 5, 2021
Q1
2021
Mar 31, 2020
$52.06M
May 6, 2021
Q3
2020
Sep 30, 2019
$50.14M
Nov 5, 2020
Q2
2020
Jun 30, 2019
$243.35M
Aug 6, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$124.84M
Nov 6, 2025
Q3
2025
Jun 30, 2025
$94.32M
Nov 6, 2025
Q2
2025
Jun 30, 2025
$94.32M
Aug 6, 2025
Q2
2025
Mar 31, 2025
$1.27M
Aug 6, 2025
Q1
2025
Mar 31, 2025
$1.27M
May 7, 2025
Q3
2025
Mar 31, 2025
$1.27M
Nov 6, 2025
Q3
2025
Sep 30, 2024
($121.35M)
Nov 6, 2025
Q3
2025
Jun 30, 2024
($120.41M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($120.41M)
Aug 6, 2025
Q3
2025
Mar 31, 2024
($251.15M)
Nov 6, 2025
Q1
2025
Mar 31, 2024
($251.15M)
May 7, 2025
Q2
2025
Mar 31, 2024
($251.15M)
Aug 6, 2025
Q3
2024
Sep 30, 2023
$215.41M
Nov 12, 2024
Q3
2024
Jun 30, 2023
($381.14M)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($381.14M)
Aug 7, 2024
Q2
2024
Mar 31, 2023
($348.43M)
Aug 7, 2024
Q1
2024
Mar 31, 2023
($348.43M)
May 8, 2024
Q3
2024
Mar 31, 2023
($348.43M)
Nov 12, 2024
Q3
2023
Sep 30, 2022
($557.56M)
Nov 9, 2023
Q3
2023
Jun 30, 2022
($565.73M)
Nov 9, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$163.11M
Nov 6, 2025
Q2
2025
Jun 30, 2025
$87.89M
Aug 6, 2025
Q1
2025
Mar 31, 2025
$11.10M
May 7, 2025
Q3
2025
Sep 30, 2024
($120.27M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($107.16M)
Aug 6, 2025
Q1
2025
Mar 31, 2024
($261.35M)
May 7, 2025
Q3
2024
Sep 30, 2023
($133.97M)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($318.72M)
Aug 7, 2024
Q1
2024
Mar 31, 2023
($371.26M)
May 8, 2024
Q3
2023
Sep 30, 2022
($438.36M)
Nov 9, 2023
Q2
2023
Jun 30, 2022
($439.40M)
Aug 2, 2023
Q1
2023
Mar 31, 2022
($443.29M)
May 4, 2023
Q3
2022
Sep 30, 2021
($462.33M)
Nov 9, 2022
Q2
2022
Jun 30, 2021
($474.84M)
Aug 8, 2022
Q1
2022
Mar 31, 2021
$70.17M
May 9, 2022
Q3
2021
Sep 30, 2020
($440.14M)
Nov 4, 2021
Q2
2021
Jun 30, 2020
($358.88M)
Aug 5, 2021
Q1
2021
Mar 31, 2020
($373.76M)
May 6, 2021
Q3
2020
Sep 30, 2019
($312.27M)
Nov 5, 2020
Q2
2020
Jun 30, 2019
($85.83M)
Aug 6, 2020